Sjonnie2 schreef op 17 september 2018 13:35:
3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for
procedures with accelerated assessment timetable)
3.2.1. viable T-cells - Orphan - ATMP - EMEA/H/C/002397
Kiadis Pharma Netherlands B.V.; adjunctive treatment in haematopoietic stem cell
transplantation (HSCT) for a malignant disease
Scope: List of Outstanding Issues
Action: For adoption
List of Questions adopted on 08.09.2017.
www.ema.europa.eu/docs/en_GB/document...